procaterol has been researched along with Centriacinar Emphysema in 2 studies
Procaterol: A long-acting beta-2-adrenergic receptor agonist.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nojiri, M | 1 |
| Mizuno, S | 1 |
| Nishiki, K | 1 |
| Kato, R | 1 |
| Nakagawa, K | 1 |
| Oikawa, T | 1 |
| Iguchi, M | 1 |
| Osanai, K | 1 |
| Ishizaki, T | 1 |
| Toga, H | 1 |
| Kitaguchi, Y | 1 |
| Yasuo, M | 1 |
| Hanaoka, M | 1 |
2 other studies available for procaterol and Centriacinar Emphysema
| Article | Year |
|---|---|
ADRB2 gene polymorphism and emphysema heterogeneity can modulate bronchodilator response in patients with emphysema.
Topics: Aged; Aged, 80 and over; Bronchodilator Agents; Female; Genetic Predisposition to Disease; Genotype; | 2018 |
Comparison of pulmonary function in patients with COPD, asthma-COPD overlap syndrome, and asthma with airflow limitation.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Airway Resistance; Asthma; Br | 2016 |